Indication
Fluenz is indicated for active immunisation for the prevention of influenza disease in children and adolescents from 2 years to less than 18 years of age.Fluenz should be used in accordance with official recommendations.
Loading your page…
Influenza, Human
Marketing Authorisation Holder: AstraZeneca AB
EMA Authorisation: 03/06/2024
INN: influenza vaccine (live attenuated, nasal)
AI Drug & Interaction Analysis
Free account required
Ask Osler about Fluenz: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.